Analysts Conflicted on These Healthcare Names: Merit Medical Systems (MMSI), LB Pharmaceuticals, Inc. (LBRX) and Cytokinetics (CYTK)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merit Medical Systems (MMSI – Research Report), LB Pharmaceuticals, Inc. (LBRX – Research Report) and Cytokinetics (CYTK – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Merit Medical Systems (MMSI)
Bank of America Securities analyst Travis Steed reiterated a Hold rating on Merit Medical Systems today and set a price target of $100.00. The company’s shares closed last Tuesday at $82.43.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Merit Medical Systems has an analyst consensus of Strong Buy, with a price target consensus of $106.14, representing a 29.8% upside. In a report released today, TipRanks – OpenAI also downgraded the stock to Hold with a $90.00 price target.
See the top stocks recommended by analysts >>
LB Pharmaceuticals, Inc. (LBRX)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on LB Pharmaceuticals, Inc., with a price target of $78.00. The company’s shares closed last Tuesday at $24.75, close to its 52-week high of $25.52.
According to TipRanks.com, Rahimi is a 5-star analyst with an average return of
Currently, the analyst consensus on LB Pharmaceuticals, Inc. is a Strong Buy with an average price target of $48.00.
Cytokinetics (CYTK)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Cytokinetics yesterday and set a price target of $101.00. The company’s shares closed last Tuesday at $70.10, close to its 52-week high of $75.71.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $92.79 average price target, representing a 35.6% upside. In a report issued on February 19, Barclays also maintained a Buy rating on the stock with a $87.00 price target.
